Marina Biotech, Inc.

BOTHELL, WA -- (Marketwired) -- 05/13/13 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, Mirna Therapeutics, has reported that they have initiated a Phase 1 clinical study of MRX34, the first miRNA to advance into ... read more

BOTHELL, WA -- (Marketwire) -- 12/06/12 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading RNAi-based drug discovery and development company, yesterday reported financial results for the nine months ended September 30, 2012, and provided an update on 2012 corporate accomplishments. "We continue to rebuild the company, and improve shareholder ... read more

BOTHELL, WA -- (Marketwire) -- 12/05/12 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's licensee, ProNAi Therapeutics, has reported results of their Phase 1 study of PNT2258, an anti-Bcl-2 cancer drug which uses the Company's SMARTICLES delivery ... read more

BOTHELL, WA -- (Marketwire) -- 12/04/12 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued United States Patent 8,314,227. The patent expands protection to the Company's Unlocked Nucleobase Analog (UNA) modification ... read more

BOTHELL, WA -- (Marketwire) -- 10/11/12 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading RNAi-based drug discovery and development company, today reported financial results for the fiscal year ended December 31, 2011, and provided an update on recent corporate accomplishments and strategic direction. "The past nine months have been an ... read more

BOTHELL, WA -- (Marketwire) -- 08/22/12 -- Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company, today provided an update on its operations. The Company continues to seek adequate funding to implement its business plan and has accomplished the following in order to generate ... read more

BOTHELL, WA -- (Marketwire) -- 08/03/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced today that it has entered into a licensing agreement with Novartis for Marina Biotech's Conformationally Restricted Nucleotide (CRN) technology for the development of both single- and double-stranded ... read more

BOTHELL, WA -- (Marketwire) -- 06/01/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that it does not currently have adequate funding to continue implementing its business plan. To conserve available cash, management has implemented a furlough of approximately 90% ... read more

BOTHELL, WA -- (Marketwire) -- 05/10/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent applications U.S. 12/004,154 ('154), U.S. 10/594,553 ('553), and U.S. ... read more

BOTHELL, WA -- (Marketwire) -- 05/08/12 -- Marina Biotech, Inc. (OTCQX: MRNA) announced today that it has entered into an exclusive licensing agreement with Monsanto Company for Marina Biotech's delivery and chemistry technologies. Terms of the agreement were not disclosed. "We are pleased to enter into this agreement with ... read more

BOTHELL, WA -- (Marketwire) -- 04/19/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that it has regained intellectual property rights to its transkingdom RNAi (tkRNAi) drug discovery platform for both agriculture and veterinary uses. The Company is currently developing ... read more

BOTHELL, WA -- (Marketwire) -- 04/03/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the completion of dosing for Cohort 2 in the Dose Escalation Phase of its START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) ... read more

BOTHELL, WA -- (Marketwire) -- 03/19/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced that it has entered into definitive agreements with certain institutional investors for a registered direct placement of approximately $1.2 million of common stock at a price ... read more

BOTHELL, WA -- (Marketwire) -- 02/29/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today reported data demonstrating the continued advancement of the Company's clinical program for CEQ508, the only orally administered RNAi therapeutic in clinical development. Data were also presented ... read more

BOTHELL, WA -- (Marketwire) -- 02/22/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 10/505,107 with claims that broadly cover a ... read more

BOTHELL, WA -- (Marketwire) -- 02/14/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the closure of its Cambridge site and the consolidation of all research and development efforts at its headquarters in Bothell, WA. In addition, the Company ... read more

BOTHELL, WA -- (Marketwire) -- 02/10/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced the closing of a bridge loan pursuant to a Note and Warrant Purchase Agreement. Under the terms of the loan, the Company sold promissory notes ... read more

BOTHELL, WA -- (Marketwire) -- 02/01/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that the Company's common stock will begin trading on the OTCQX tier of the OTC Markets commencing on Thursday, February 2, 2012. The Company has ... read more

BOTHELL, WA -- (Marketwire) -- 01/25/12 -- Marina Biotech, Inc. (NASDAQ: MRNA), a leading nucleic acid-based drug discovery and development company, today announced that Cohort 2 in the Dose Escalation Phase of the START-FAP (Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis) clinical trial with ... read more

BOTHELL, WA -- (Marketwire) -- 01/23/12 -- Marina Biotech, Inc. (NASDAQ: MRNAD), a leading oligonucleotide-based drug discovery and development company today announced that the Intellectual Property Office of New Zealand (IPONZ) has issued a Notice of Acceptance for patent application 580712. The claims broadly cover multiple sequence independent and ... read more